Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exelixis (EXEL) PT Bumped to $8 at Piper Jaffray, Remains Sidelined
August 4, 2016 7:21 AM EDTPiper Jaffray analyst Edward Tenthoff raised his price target on Exelixis (NASDAQ: EXEL) to $8.00 (from $5.00) but maintained a Neutral rating following results.
Tenthoff commented, "Exelixis reported COMETRIQ sales of $14M in 2Q:16 and CABOMETYX renal cell carcinoma (RCC) sales of $17.6M including... More
Exelixis (EXEL) Tops Q2 EPS by 11c, Revenue Tops Views
August 3, 2016 4:43 PM EDTExelixis (NASDAQ: EXEL) reported Q2 EPS of ($0.16), $0.11 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $36.3 million versus the consensus estimate of $17.96 million.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
... More